Loading data for HOWL — first visit, this takes a few seconds.

Preisalarm

Werewolf Therapeutics Inc... (HOWL)

NasdaqCM: HOWL · Echtzeitkurs · USD

0.41

+0.00 (0.00%)

Zum Schluss: Aug 18, 2026, 8:00 PM

0.00% (1D)

Keine Daten verfügbar

Geld	0.29
Marktkapitalisierung	19.89 Mio
Umsatz (TTM)	21 Mio
Nettogewinn (TTM)	-34.61 Mio
Beta	0.29
EPS (ttm)	-0.75
KGV (TTM)	n/a
Forward-KGV	-0.41
KBV (TTM)	1.22
KUV (TTM)	0.95
Earnings Date	Oct 30, 2026

Brief	0.53
Volumen	87,024
Ø Vol. (20D)	713,301
Eröffnung	0.40
Vortagesschluss	0.41
Tagesspanne	0.40 - 0.41
52-Wk Range	0.27 - 2.38
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über HOWL

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead prod...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Apr 30, 2021

Mitarbeiter 39

Börse NasdaqCM

Tickersymbol HOWL

Website https://werewolftx.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Werewolf Therapeutics 0, ein Rückgang von -100% im Vergleich zum Vorjahr (1.89 Mio). Der Gewinn lag bei -60.82 Mio, ein Rückgang von -13.75 %.

Finanzberichte

Gewinnüberraschung

Werewolf Therapeutics hat die Quartalszahlen am Jul 31, 2026 veröffentlicht:

Umsatz von $21 Mio verfehlt die Erwartungen um $0, mit Infinity% Wachstum im Jahresvergleich.

EPS von 0.14 übertrifft die Erwartungen um 0.46, mit 135.00% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Werewolf Therapeutics Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Oct 30, 2026, vor Börseneröffnung.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 2 Wochen · Zacks

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.

vor 3 Monaten · Simply Wall St.

Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

vor 7 Monaten · Insider Monkey

Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is included on our list of stocks under $1 that will explode. On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline ...

vor 8 Monaten · Zacks

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

vor 9 Monaten · Zacks

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake

INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.

Seite 1 von 2

Werewolf Therapeutics Inc... (HOWL)